Jonathan Feldschuh - 11 Jul 2023 Form 4 Insider Report for DAXOR CORP (DXR)

Role
Chief Scientific Officer, Director
Signature
/s/ Jonathan Feldschuh
Issuer symbol
DXR
Transactions as of
11 Jul 2023
Net transactions value
$0
Form type
4
Filing time
13 Jul 2023, 16:48:03 UTC
Next filing
10 Dec 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DXR Stock Options (right to buy) Award $0 +25,000 $0.000000 25,000 11 Jul 2023 COMMON STOCK 25,000 $9.88 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options granted on July 11, 2023 are contingent on the approval of the Securities & Exchange Commission ("SEC") to amend the Daxor Corporation 2020 Incentive Compensation Plan (the "Plan").
F2 The stock options will vest in three installments on July 11, 2024 (8,333), July 11, 2025 (8,333) and July 11, 2026 (8,334)